Meanwhile, eribulinmesylate, an FDA-approved drug for breast cancer and liposarcoma, has been shown to effectively and specifically inhibit the RNA-dependent RNA polymerase activity of TERT in multiple human GBM cell lines in preclinical mouse brain tumor models. This evidence concerns the gene TERT and glioblastoma.